0001193125-20-168819.txt : 20200716 0001193125-20-168819.hdr.sgml : 20200716 20200615124102 ACCESSION NUMBER: 0001193125-20-168819 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200615 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intersect ENT, Inc. CENTRAL INDEX KEY: 0001271214 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 200280837 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1555 ADAMS DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-641-2100 MAIL ADDRESS: STREET 1: 1555 ADAMS DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: SINEXUS INC DATE OF NAME CHANGE: 20031124 CORRESP 1 filename1.htm Acceleration Request

INTERSECT ENT, INC.

1555 Adams Drive

Menlo Park, CA 94025

June 15, 2020

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn:

Ada D. Sarmento

 

RE:

Intersect ENT, Inc.

    

Registration Statement on Form S-3

    

File No. 333-238963

Acceleration Request

  Requested Date:

June 17, 2020

  Requested Time:

4:00 p.m. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-238963) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on Wednesday, June 17, 2020, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Matthew B. Hemington of Cooley LLP, counsel to the registrant, at (650) 843-5062.

[Signature page follows]

Sincerely,
INTERSECT ENT, INC.
By:  

/s/ Thomas A. West

  Thomas A. West
  President and Chief Executive Officer

 

cc:

Richard A. Meier, Executive Vice President and Chief Financial Officer, Intersect ENT, Inc.

    

Matthew B. Hemington, Cooley LLP